financetom
Business
financetom
/
Business
/
BASF post slight Q1 earnings drop but beats forecast
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
BASF post slight Q1 earnings drop but beats forecast
Apr 24, 2024 10:07 PM

BERLIN (Reuters) -Germany's BASF said first-quarter adjusted earnings fell 5.3% year on year, primarily due to higher bonus provisions, but still came in above analysts' consensus.

In a statement on Thursday, the German chemicals giant said quarterly earnings before interest, taxes, depreciation and amortisation (EBITDA), adjusted for one-off items, was 2.7 billion euros ($2.89 billion), above the average analyst estimate of 2.57 billion, according to a consensus posted on the company's website.

Sales fell by about 12% to 17.6 billion euros in the first quarter, as BASF feels the effect of lower prices in almost all segments, missing forecasts for 18.6 billion euros.

The company also confirmed its previous adjusted earnings forecast for between 8 billion and 8.6 billion euros in 2024, up from 7.67 billion last year.

($1 = 0.9340 euros)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Regeneron Pharmaceuticals Insider Sold Shares Worth $1,115,422, According to a Recent SEC Filing
Regeneron Pharmaceuticals Insider Sold Shares Worth $1,115,422, According to a Recent SEC Filing
Jun 5, 2024
04:13 PM EDT, 06/05/2024 (MT Newswires) -- Marion McCourt, Executive Vice President, Commercial, on June 03, 2024, sold 1,138 shares in Regeneron Pharmaceuticals ( REGN ) for $1,115,422. Following the Form 4 filing with the SEC, McCourt has control over a total of 13,105 shares of the company, with 12,931 shares held directly and 174 controlled indirectly. SEC Filing: https://www.sec.gov/Archives/edgar/data/872589/000196820224000100/xslF345X03/edgardoc.xml...
Celldex Therapeutics Insider Sold Shares Worth $1,964,088, According to a Recent SEC Filing
Celldex Therapeutics Insider Sold Shares Worth $1,964,088, According to a Recent SEC Filing
Jun 5, 2024
04:14 PM EDT, 06/05/2024 (MT Newswires) -- Margo Heath-Chiozzi, Senior Vice President, Regulatory Affairs, on June 03, 2024, sold 58,369 shares in Celldex Therapeutics ( CLDX ) for $1,964,088. Following the Form 4 filing with the SEC, Heath-Chiozzi has control over a total of 13,383 shares of the company, with 13,383 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/744218/000141588924015544/xslF345X03/form4-06052024_080636.xml ...
--ChargePoint Guides For Q2 Revenue of $108-$118 Million, vs CIQ Analyst Consensus of $123 Million
--ChargePoint Guides For Q2 Revenue of $108-$118 Million, vs CIQ Analyst Consensus of $123 Million
Jun 5, 2024
04:13 PM EDT, 06/05/2024 (MT Newswires) -- Price: 1.7700, Change: +0.05, Percent Change: +2.91 ...
Springworks Therapeutics Insider Sold Shares Worth $801,372, According to a Recent SEC Filing
Springworks Therapeutics Insider Sold Shares Worth $801,372, According to a Recent SEC Filing
Jun 5, 2024
04:13 PM EDT, 06/05/2024 (MT Newswires) -- Badreddin Edris, Chief Operating Officer, on June 03, 2024, sold 20,000 shares in Springworks Therapeutics ( SWTX ) for $801,372. Following the Form 4 filing with the SEC, Edris has control over a total of 249,600 shares of the company, with 249,600 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1773427/000110465924068673/xslF345X03/tm2416457-1_4seq1.xml ...
Copyright 2023-2026 - www.financetom.com All Rights Reserved